Research Candidates

 
News Articles for Research Candidates top ^
http://media.marketwire.com/attachments/201310/67049_medicinescompany.jpg http://media.marketwire.com/attachments/201310/67050_alnylam.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1057964&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for The Medicines Company and Alnylam Advance Development Candidate for ALN-PCSsc, a Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation for the Treatment of Hypercholesterolemia investment picks
The Medicines Company (Nasdaq: MDCO) a leading acute/intensive hospital care company, and Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that their strategic alliance has yielded a lead Development Candidate that is a subcutaneously administered RNAi therapeutic (ALN-PCSsc) targeting PCSK9 for the potential treatment of hypercholesterolemia.
Sign-up for The Medicines Company and Alnylam Advance Development Candidate for ALN-PCSsc, a Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation for the Treatment of Hypercholesterolemia investment picks
BELLUS Health and AmorChem Announce a Partnership to Develop Drug Candidates for AL Amyloidosis Canada NewsWire LAVAL, QC , Oct.
Sign-up for BELLUS Health and AmorChem Announce a Partnership to Develop Drug Candidates for AL Amyloidosis investment picks
2014/2/4
Right Management's Career Transition Solutions Bolstered by Workfolio's Innovative Personal Website Technology Platform MILWAUKEE , Feb.
Sign-up for Right Management to Offer Personal Websites to Transitioning Candidates through Partnership with Workfolio investment picks
2014/3/6
REDWOOD CITY, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it will provide an extensive update on its anti-cancer stem cell pipeline at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 in at the San Diego Convention Center in San Diego, CA.
Sign-up for OncoMed to Present Data on Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting investment picks
NanoViricides, Inc. (OTC BB: NNVC ) (the "Company") said it has signed a non-disclosure agreement (NDA) with the Lovelace Respiratory Research Institute (“LRRI”). The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide® drug candidates.
Sign-up for NanoViricides Signs a Non-Disclosure Agreement with the Lovelace Respiratory Research Institute for IND-enabling Efficacy Studies on FluCide® and for Testing its Novel Drug Candidates against the Highly Lethal MERS Human Coronavirus investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it will present at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) the results of important research that supports the potential of the company’s next-generation antibiotics portfolio, including its lead candidate eravacycline in the treatment of difficult-to-treat bacterial infections (e.g., serious Gram-negative and biothreat infections). Data to be presented will highlight dosing of eravacycline in the company’s Phase 2 clinical trial in complicated intra-abdominal infections (cIAI) as well as its activity in preclinical studies against neisseria gonorrhoeae , a common but increasingly resistant cause of gonococcal disease.
Sign-up for Tetraphase to Present Data at ICAAC Supporting Its Lead Antibiotic Candidate Eravacycline’s Effectiveness against Multi-drug Resistant (MDR) Pathogens investment picks
--First therapeutic vaccine candidate to demonstrate significant reduction in viral shedding --Results demonstrate that immunization with GEN-003 is associated with activation of T cell immunity --Genocea to initiate Phase 2 study in 2014 CAMBRIDGE, Mass.
Sign-up for Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013 investment picks
SAN FRANCISCO (MarketWatch) -- Ford (F) CEO Alan Mulally could be one of the lead candidates for the top job at Microsoft (MSFT), according to a report by the AllThingsD technology blog on Thursday afternoon.
Sign-up for Ford CEO lead candidate for Microsoft - report investment picks
By John Kell Shares of Lpath Inc. (LPTN) slid in after-hours trading Tuesday, after the biotechnology company warned Pfizer Inc. (PFE) may divest its exclusive option to co-develop the smaller firm's leading product candidate.
Sign-up for Lpath Shares Fall as Pfizer May Divest Product Candidate Option investment picks
2013/10/8
German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it will conduct Phase III studies on five drug candidates in the areas of oncology, cardiology and women's health by the year 2015.
Sign-up for Bayer to Conduct Phase III Studies on 5 Drug Candidates by 2015 investment picks
Agenus Inc. (NASDAQ: AGEN) today announced that new Phase 3 data for GlaxoSmithKline’s (NYSE: GSK) RTS,S malaria vaccine candidate, which contains Agenus’ QS-21 Stimulon ®1 adjuvant, were presented at a Multilateral Initiative on Malaria Pan African Conference in Durban, South Africa.
Sign-up for GSK’s Vaccine Candidate Containing Agenus’ QS-21 Stimulon® Reduces Malaria Infection in Phase 3 Trials of Over 15,000 Children investment picks
Retrophin, Inc. (OTCQB: RTRX) today announced its newest clinical development candidate RE-034 (cosyntropin), a long-acting synthetic analog (amino acids 1-24) of the naturally-occurring adrenocorticotropic hormone (ACTH) formulated with zinc.
Sign-up for Retrophin Unveils New Clinical Development Candidate RE-034, An ACTH Analog investment picks
2013/12/17
Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn’s disease.
Sign-up for Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe investment picks
2014/2/1
NEW YORK (MarketWatch) - Nathan Sheets, a senior economist at Citigroup and a former adviser to departing Federal Reserve Chairman Ben Bernanke, is a top candidate for the Treasury Department's top international affairs post, Reuters reported late Friday, citing unnamed sources.
Sign-up for Citi economist candidate for Treasury post: report investment picks
By Shalini Ramachandran and Liz Hoffman Charter Communications Inc. put forward a group dominated by cable industry veterans and former investment bankers as candidates for Time Warner Cable Inc.'s board at its annual shareholder meeting this spring, opening the next phase of its battle to take control of the second-biggest U.S. cable operator.
Sign-up for Charter Nominates Candidates for Time Warner Cable Board -- Update investment picks
2014/2/10
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes.
Sign-up for Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Candidates
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Campus  |  Next: Research Capabilities